Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

School of Public Health: Chemtob Daniel

Researchers / חוקרים

 Last updated December 2021 - School of Public Health

List of Publications

(1) Chemtob D, Weil C, Attal JH, Hawila E, Sadeh EN. HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis. PLoS ONE 2021;16(11 November).

(2) Chemtob D, Levy I, Kaufman S, Averick N, Krauss A, Turner D. Drop-out of medical follow-up among people living with HIV in Tel-Aviv area. AIDS Care Psychol Socio-Med Asp AIDS HIV 2021.

(3) Chemtob D, Ogum E. Tuberculosis treatment outcomes of non-citizen migrants: Israel compared to other high-income countries. Isr J Health Policy Res 2020;9(1).

(4) Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV 2020;7(6):e434-e442.

(5) Chowers M, Chemtob D, Mor O, Levy I, Elbirt D, Elinav H, et al. Continuum of HIV care of newly diagnosed individuals in Israel, 2011–2015: a population-based cohort study. Int J STD AIDS 2020;31(4):326-334.

(6) Ginsberg GM, Chemtob D. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health 2020;20(1).

(7) Bishara H, Green M, Chemtob D, Saffouri A, Zelikman L, Weiler-Ravell D. Ongoing tuberculosis transmission among second-generation Ethiopian immigrants in Israel. Epidemiol Infect 2020.

(8) Mårdh O, Quinten C, Kuchukhidze G, Seguy N, Dara M, Amato-Gauci AJ, et al. HIV among women in the WHO European Region – Epidemiological trends and predictors of late diagnosis, 2009-2018. Eurosurveillance 2019;24(48).

(9) Chemtob D, Rich R, Harel N, Averick N, Schwartzberg E, Yust I, et al. Ensuring HIV care to undocumented migrants in Israel: a public-private partnership case study. Isr J Health Policy Res 2019;8(1).

(10) Hayes R, Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P, et al. Estimating the 'PrEP Gap': How implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance 2019;24(41).

(11) Chemtob D, Mor Z, Harel N, Averick N. HIV infection among men who have sex with men in Israel: A 35-year epidemiological and clinical overview, 1981-2015. BMC Public Health 2019;19(1).

(12) Ganzel C, Silverman B, Chemtob D, Ben Shoham A, Wiener-Well Y. The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study. Leuk Lymphoma 2019;60(3):720-725.

(13) Kiros YK, Elinav H, Gebreyesus A, Gebremeskel H, Azar J, Chemtob D, et al. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV Med 2019;20(1):33-37.

(14) Brown AE, Hayes R, Noori T, Azad Y, Amato-Gauci AJ, Pharris A, et al. HIV in Europe and central Asia: Progress in 2018 towards meeting the UNAIDS 90-90-90 targets. Eurosurveillance 2018;23(48).

(15) Bui LV, Mor Z, Chemtob D, Ha ST, Levine H. Use of geographically weighted poisson regression to examine the effect of distance on tuberculosis incidence: A case study in Nam Dinh, Vietnam. PLoS ONE 2018;13(11).

(16) Avidor B, Chemtob D, Turner D, Zeldis I, Girshengorn S, Matus N, et al. Evaluation of the virtues and pitfalls in an HIV screening algorithm based on two fourth generation assays – A step towards an improved national algorithm. J Clin Virol 2018;106:18-22.

(17) Popovici O, Monk P, Chemtob D, Chiotan D, Freidlin PJ, Groenheit R, et al. Cross-border outbreak of extensively drug-resistant tuberculosis linked to a university in Romania. Epidemiol Infect 2018;146(7):824-831.

(18) Rakovsky A, Gozlan Y, Bassal R, Wax M, Shirazi R, Bakhanashvili M, et al. Diagnosis of HIV-1 infection: Performance of Xpert Qual and Geenius supplemental assays in fourth generation ELISA-reactive samples. J Clin Virol 2018;101:7-10.

(19) Mor Z, Sheffer R, Chemtob D. Causes of death and mortality trends of all individuals reported with HIV/AIDS in Israel, 1985-2010. J Public Health 2018;40(1):56-64.

(20) Mor Z, Sheffer R, Chemtob D. Mother-to-child HIV transmissions in Israel, 1985-2011. Epidemiol Infect 2017;145(9):1913-1921.

(21) Katchman E, Ben-Ami R, Savyon M, Chemtob D, Avidor B, Wasserman A, et al. Successful control of a large outbreak of HIV infection associated with injection of cathinone derivatives in Tel Aviv, Israel. Clin Microbiol Infect 2017;23(5):336.e5-336.e8.

(22) Chemtob D, Gandacu D, Mor Z, Grotto I, Anis E, Rosenberg E. A national strategic plan for reducing the burden of sexually transmitted infections in Israel by the year 2025. Isr J Health Policy Res 2017;6(1).

(23) Freidlin PJ, Nissan I, Luria A, Goldblatt D, Schaffer L, Kaidar-Shwartz H, et al. Structure and variation of CRISPR and CRISPR-flanking regions in deleted-direct repeat region Mycobacterium tuberculosis complex strains. BMC Genomics 2017;18(1).

(24) Chowers M, Regev-Yochay G, Mor O, Cohen-Poradosu R, Riesenberg K, Zimhony O, et al. Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009–2014. Hum Vaccines Immunother 2017;13(1):216-219.

(25) Ginsberg GM, Shinar E, Kopel E, Chemtob D. Should Men who have sex with Men be allowed to donate blood in Israel. Isr J Health Policy Res 2016;5(1).

(26) Mor Z, Lidji M, Chemtob D, Cedar N, Grotto I. Erratum: 'HIV prevalence in the Israeli tuberculosis cohort, 1999-2011' (BMC Public Health (2014) 14 (1090)). BMC Public Health 2016;16(1).

(27) Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis 2016;62(5):655-663.

(28) Shuldiner J, Leventhal A, Chemtob D, Mor Z. Mortality after anti-tuberculosis treatment completion: Results of long-term follow-up. Int J Tuberc Lung Dis 2016;20(1):43-48.

(29) Chemtob D, Op de Coul E, van Sighem A, Mor Z, Cazein F, Semaille C. Impact of Male Circumcision among heterosexual HIV cases: Comparisons between three low HIV prevalence countries. Isr J Health Policy Res 2015;4(1).

(30) Chemtob D, Mor Z, Grotto I. Tuberculosis screening programmes for migrants to low-incidence countries-the Israeli experience. Lancet Infect Dis 2015;15(8):876.

(31) Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, De Vries G, Diel R, et al. Towards tuberculosis elimination: An action framework for low-incidence countries. Eur Respir J 2015;45(4):928-952.

(32) Mor Z, Goldblatt D, Kaidar-Shwartz H, Cedar N, Rorman E, Chemtob D. Drug-resistant tuberculosis in Israel: Risk factors and treatment outcomes. Int J Tuberc Lung Dis 2014;18(10):1195-1201.

(33) Goldblatt D, Rorman E, Chemtob D, Freidlin PJ, Cedar N, Kaidar-Shwartz H, et al. Molecular epidemiology and mapping of tuberculosis in Israel: Do migrants transmit the disease to locals? Int J Tuberc Lung Dis 2014;18(9):1085-1091.

(34) Frentz D, Van de Vijver DAMC, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis 2014;14(1).

(35) Shuldiner J, Leventhal A, Chemtob D, Mor Z. Mortality of tuberculosis patients during treatment in israel, 2000-2010. Int J Tuberc Lung Dis 2014;18(7):818-823+ii.

(36) D'Ambrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, Van Der Werf MJ, et al. Tuberculosis elimination: Theory and practice in Europe. Eur Respir J 2014;43(5):1410-1420.

(37) Mor Z, Lidji M, Cedar N, Grotto I, Chemtob D. Tuberculosis incidence in HIV/AIDS patients in Israel, 1983-2010. PLoS ONE 2013;8(11).

(38) Mor Z, Weinstein R, Grotto I, Levin Y, Chemtob D. Thirty years of HIV in Israel: Current epidemiology and future challenges. BMJ Open 2013;3(7).

(39) Frentz D, Wensing AMJ, Albert J, Paraskevis D, Abecasis AB, Hamouda O, et al. Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology 2013;10(1).

(40) Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DAMC, Albert J, et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012;9.

(41) Chemtob D, Zenilman JM, Gandacu D. What do we need to learn for policy decision-making on sexually transmitted infections prevention and treatment in Israel? Int J STD AIDS 2012;23(9):e11-e15.

(42) Merrick J, Talnir R, Gross S, Chemtob D, Aspler S, Kandel I, et al. Human immunodeficiency virus (HIV) and persons with disability/intellectual disability. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 23-30.

(43) Schenker I, Chemtob D, Yamin N, Shtechman N, Rosenberg H. The National HIV/AIDS hotline in Israel: Data on utilization, quality assurance and content. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 107-115.

(44) Chemtob D, Gurevitz M, Levitt S, Basudo-Manor N, Shufman E, Maayan S. Epidemiology of Hepatitis B, Hepatitis C and HIV infections among intravenous drug users in Jerusalem, Israel. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 117-126.

(45) Chemtob D, Merrick J. Introduction: Preventing and treating tuberculosis and HIV/AIDS. A worldwide public health challenge. AIDS and Tuberc : Public Health Asp 2012:xvii-xx.

(46) Chemtob D, Merrick J. AIDS and Tuberculosis: Public Health Aspects. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 1-168.

(47) Chemtob D, Rosenberg E. Healthy Israel 2020: Objectives, targets, and evidence-based strategies to prevent tuberculosis and HIV infection in Israel. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 31-46.

(48) Gross S, Merrick J, Talnir R, Aspler S, Kandel I, Morad M, et al. Human immunodificiency virus (HIV) in a residential care center for persons with intellectual disability in Israel: A needle in a haystack investigation. AIDS and Tuberculosis: Public Health Aspects; 2012. p. 133-141.

(49) Mor Z, Davidovich U, Bessudu-Manor N, McFarlane M, Feldshtein G, Chemtob D. High-risk behaviour in steady and in casual relationships among men who have sex with men in Israel. Sex Transm Infect 2011;87(6):532-537.

(50) Alvarez GG, Clark M, Altpeter E, Douglas P, Jones J, Paty M-, et al. Pediatric tuberculosis immigration screening in high-immigration, low-incidence countries (International Journal of Tuberculosis and Lung Disease (2010) 14, 12, (1530-1537)). Int J Tuberc Lung Dis 2011;15(3):425.

(51) Alvarez GG, Gushulak B, Rumman KA, Altpeter E, Chemtob D, Douglas P, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis 2011;11.

(52) Alvarez GG, Clark M, Altpeter E, Douglas P, Jones J, Paty M-, et al. Pediatric tuberculosis immigration screening in high-immigration, low-incidence countries. Int J Tuberc Lung Dis 2010;14(12):1530-1537.

(53) Erkens CGM, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, et al. Tuberculosis contact investigation in low prevalence countries: A European consensus. Eur Respir J 2010;36(4):925-949.

(54) Chemtob D, Levy A. Rationale and staff evaluation of using a therapeutic milieu for substance users within a tuberculosis ward. Subst Use Misuse 2009;44(5):672-683.

(55) Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: A nationwide cohort. Thorax 2009;64(3):271.

(56) Bothamley GH, Ditiu L, Migliori GB, Lange C, Hafizi H, Mezhlumyan N, et al. Active case finding of tuberculosis in Europe: A Tuberculosis Network European Trials Group (TBNET) survey. Eur Respir J 2008;32(4):1023-1030.

(57) Mor Z, Davidovich U, McFarlane M, Feldshtein G, Chemtob D. Gay men who engage in substance use and sexual risk behaviour: A dual-risk group with unique characteristics. Int J STD AIDS 2008;19(10):698-703.

(58) Chemtob D, Levit S, Mell H, Margolis A, Levy A, Leventhal A. "Injecting clean or being clean?" The International and Israeli experiences of Syringe Exchange Programs among injecting drugs users. Harefuah 2008;147(7):634-638.

(59) Chemtob D. Mortality of hospitalized tuberculosis patients in Israel. Isr Med Assoc J 2008;10(3).

(60) Mor Z, Adler A, Leventhal A, Volovic I, Rosenfeld E, Lobato MN, et al. Tuberculosis behind bars in Israel: Policy making within a dynamic situation. Isr Med Assoc J 2008;10(3):202-206.

(61) Mor Z, Chemtob D, Hildesheimer GM, Leventhal A. Aids and the right to privacy. Harefuah 2007;146(3):200-205.

(62) Chemtob D, Sasson M, Leventhal A, Stein-Zamir C, Maayan S. Sexually transmitted infections among individuals with and without HIV [1]. Isr Med Assoc J 2006;8(12):892.

(63) Mor Z, Chemtob D, Pessach N, Nitzan-Kaluski D. Human immunodeficiency virus in newborn of infected mothers: Pregnancy, breast feeding and prevention. Harefuah 2006;145(9):682-686.

(64) Chemtob D, Damelin B, Bessudo-Manor N, Hassman R, Amikam Y, Zenilman JM, et al. "Getting AIDS: Not in my back yard." Results from a national knowledge, attitudes and practices survey. Isr Med Assoc J 2006;8(9):610-614.

(65) Chemtob D, Weiler-Ravell D, Leventhal A, Bibi H. Epidemiologic characteristics of pediatric active tuberculosis among immigrants from high to low tuberculosis-endemic countries: The Israeli experience. Isr Med Assoc J 2006;8(1):21-26.

(66) Chemtob D, Srour SF. Epidemiology of HIV infection among Israeli Arabs. Public Health 2005;119(2):138-143.

(67) Chemtob D, Grossman Z. Epidemiology of adult and adolescent HIV infection in Israel: A country of immigration. Int J STD AIDS 2004;15(10):691-696.

(68) Weiler-Ravell D, Leventhal A, Berlowitz Y, Rishpon S, Chemtob D. Circumstances leading to the formulation and implementation of a new TB control program in Israel: A case study in public health and policy. J Public Health Policy 2004;25(1):23-37.

(69) Weiler-Ravell D, Leventhal A, Coker RJ, Chemtob D. Compulsory detention of recalcitrant tuberculosis patients in the context of a new uberculosis control programme in Israel. Public Health 2004;118(5):323-328.

(70) Chemtob D, Leventhal A, Weiler-Ravell D. Screening and management of tuberculosis in immigrants: The challenge beyond professional competence. Int J Tuberc Lung Dis 2003;7(10):959-966.

(71) Chemtob D, Leventhal A, Berlowitz Y, Weiler-Ravell D. The new National Tuberculosis Control Programme in Israel, a country of high immigration. Int J Tuberc Lung Dis 2003;7(9):828-836.

(72) Leventhal A, Berlowitz Y, Chemtob D. Migrant workers: Evolution of the Israel health system approach to the new social issue. Harefuah 2003;142(8-9):632-635+644.

(73) Chemtob D, Nitzan Kaluski D. Political commitment and public health prioritization. Isr Med Assoc J 2002;4(3):234.

(74) Bibi H, Weiler-Ravell D, Shoseyov D, Feigin I, Arbelli Y, Chemtob D. Compliance to treatment of latent tuberculosis infection in a region of Israel. Isr Med Assoc J 2002;4(1):13-16.

(75) Chemtob D, Leventhal A, Weiler-Ravell D. Tuberculosis in Israel--main epidemiological aspects. Harefuah 2002;141(3):226-232, 316.

(76) Chemtob D, Leventhal A, Berlowitz Y, Weiler-Ravell D. The new national program for tuberculosis elimination in Israel. Harefuah 2002;141(3):265-271, 314.

(77) Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, et al. Erratum: Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B (AIDS (2001) 15 (1453-1460)). [1]. AIDS 2001;15(16):2209.

(78) Chemtob D, Epstein L, Slater PE, Weiler-Ravell D. Epidemiological analysis of tuberculosis treatment outcome as a tool for changing TB control policy in Israel. Isr Med Assoc J 2001;3(7):479-483.

(79) Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B. AIDS 2001;15(12):1453-1460.

(80) Ravins M, Bercovier H, Chemtob D, Fishman Y, Rahav G. Molecular epidemiology of Mycobacterium tuberculosis infection in Israel. J Clin Microbiol 2001;39(3):1175-1177.

(81) Chemtob D, Weiler-Ravell D, Ben-Dov I. Incorrect estimation of TB drug resistance in Israel, probably due to recruitment and collection biases [2] (multiple letters). Int J Tuberc Lung Dis 2000;4(10):990-992.

(82) Srour-Fihmi S, Weiler-Ravell D, Kitzes R, Chemtob D. Routine two-step skin testing for tuberculosis in the staff of a geriatric hospital in Israel: Booster and conversion rates. J Hosp Infect 2000;46(2):141-146.

(83) Senba M, Chemtob D, Slater PE, Fassberg J, Larouze B. Prevention of chronic carriage of hepatitis B virus infection in Ethiopian immigrants [2]. Isr J Med Sci 1992;28(5):308-309.

(84) Chemtob D, Fassberg J, Kalka I, Harlap S, Slater PE, Ever-Hadani P, et al. Prevention strategy of hepatitis B virus infection among the Ethiopian Community in Israel. Isr J Med Sci 1991;27(5):273-277.

(85) Chemtob D, Kalka I, Fassberg Y. Research note: Blood drawing and hepatitis B ‐‐ the case of Ethiopian Jews in Israel. Sociol Health Illn 1990;12(2):216-226.